Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAR19-BCMA CAR-T cells
- Development stage
- Unknown
- Lead developer
- Chinese PLA General Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CAR19-BCMA CAR-T cells is a dual-targeted chimeric antigen receptor (CAR) T-cell therapy designed to simultaneously target B-cell maturation antigen (BCMA) and CD19. Developed by The Four Medical Center of PLA General Hospital, this autologous cell therapy is intended for the treatment of relapsed or refractory plasma cell neoplasms, including multiple myeloma, plasmacytoma, and plasma cell leukemia. By targeting BCMA, which is highly expressed on malignant plasma cells, and CD19, which is expressed on B-cell progenitors and potentially a subset of myeloma stem cells, the therapy aims to reduce the risk of antigen-escape-mediated relapse and improve the durability of clinical responses. It is currently undergoing Phase 1 clinical evaluation in China to assess safety, tolerability, and preliminary efficacy.
- Other names
- CAR19-BCMA dual-target CAR-TCAR-19-BCMA dual-target CAR-TCAR 19-BCMA dual-target CAR-TCAR19-BCMA dual-target CAR-T cellsCAR-19-BCMA dual-target CAR-T cellsCAR 19-BCMA dual-target CAR-T cells
02
Targets
CD19 (B lymphocyte antigen CD19)BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on CAR19-BCMA CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAR19-BCMA CAR-T cells.